Core Insights - The first brain-computer interface (BCI) surgery in China was successfully completed at Tongji Hospital in Wuhan, marking a significant step in integrating BCI technology into the medical service pricing system [1][2] - The surgery was performed on a paraplegic patient and was funded by research grants, highlighting the importance of establishing a clear pricing standard for BCI procedures [1][2] - The procedure utilized a BCI device produced by Wuhan Zhonghua Brain-Machine Fusion Technology Development Co., which specializes in BCI technology research and industrialization [2] Industry Developments - The National Healthcare Security Administration guided the establishment of a standardized pricing for invasive BCI procedures, setting the cost at 6,552 yuan per operation, which facilitates the inclusion of BCI technology into the regular medical service system [1] - The successful implementation of this surgery indicates a shift from research exploration to clinical application, paving the way for broader adoption of BCI technology in medical practices [1][2] - Zhonghua Brain-Machine is focused on developing implantable BCI systems, neural signal processing algorithms, and clinical application solutions, positioning itself as a key player in the BCI industry [2]

Core Insights - The article discusses the successful implantation of a brain-computer interface (BCI) in a spinal cord injury patient in China, marking a significant advancement in the clinical application of BCI technology [3][4] - This procedure is the first in China to be executed under a government-approved medical service pricing system, indicating a shift from research to standardized medical practice for BCI [3][4] Group 1: Clinical Application of BCI - The first invasive BCI surgery in China was performed on a 31-year-old patient, who suffered from high-level paraplegia due to an accident, using a device with 64-channel flexible electrodes to monitor brain signals [3] - The surgery was conducted at Huazhong University of Science and Technology's Tongji Hospital, with the procedure costing 6,552 yuan per instance, excluding the cost of the BCI device [3][4] Group 2: Policy and Regulatory Framework - In March 2023, the Hubei Provincial Medical Insurance Bureau established the first national pricing for BCI medical services, setting the invasive BCI implantation fee at 6,552 yuan per instance [4] - The implementation of this pricing policy is seen as a crucial step in integrating BCI technology into the standardized medical treatment system, paving the way for broader clinical applications in the future [4]

Core Insights - The first clinical implantation of a brain-computer interface (BCI) in China was successfully completed at Huazhong University of Science and Technology Tongji Hospital, marking a significant step in the commercialization and accessibility of BCI technology [1][2] - The procedure is the first to be executed under a government-approved medical service pricing project, indicating a shift from research to clinical application [2][3] Group 1: Clinical Implementation - The surgery was performed on a 31-year-old patient with spinal cord injury, utilizing a BCI device with 64-channel flexible electrodes to monitor brain signals related to hand movement and sensation [1][2] - The operation was funded by research grants, as BCI technology is still in the clinical trial phase and has not yet entered market application [2] Group 2: Policy and Pricing - In March 2025, Hubei Province will implement the first national pricing project for BCI medical services, establishing fees for invasive and non-invasive procedures [2] - The invasive BCI implantation fee is set at 6,552 yuan per procedure, with additional fees for extraction and non-invasive adaptation, providing a regulatory framework for clinical application [2] Group 3: Future Implications - The successful execution of this surgery is seen as a foundational step for future large-scale clinical applications of BCI technology, establishing a critical institutional basis for subsequent healthcare reimbursements [3]

（文章来源：第一财经） 人民财讯11月27日电，11月26日，31岁的脊髓损伤患者小刘（化名）在华中科技大学附属同济医院神经 外科顺利完成了植入式脑机接口手术，开启我国脑机接口（BCI）临床应用的新阶段。 本次手术是我国首例按照政府核定医疗服务价格项目执行的脑机接口临床操作（即侵入式脑机接口置入 费6552元/次，不含脑机接口设备等费用），标志着脑机接口技术从科研探索阶段正式进入医疗服务收 费目录体系，在推动技术普惠化与产业化方面迈出重要一步。 ...

Core Insights - The first clinical application of invasive brain-computer interface (BCI) in China has been successfully performed, marking a new phase in the country's BCI development [1] - The procedure was conducted at Huazhong University of Science and Technology's Tongji Hospital, with a government-approved service price of 6552 yuan per procedure, excluding the cost of the BCI device [1][5] - This development signifies the transition of BCI technology from research to a standardized medical service, paving the way for broader accessibility and industrialization [1][5] Summary by Sections - **Clinical Application**: The first invasive BCI surgery was performed on a 31-year-old patient with spinal cord injury, demonstrating the potential of BCI technology in clinical settings [1] - **Cost Structure**: The established cost for the invasive BCI procedure is 6552 yuan per session, which is a significant step towards integrating BCI into the healthcare payment system [5] - **Regulatory Framework**: The implementation of a standardized pricing model for BCI procedures by the Hubei Provincial Medical Insurance Bureau is a pioneering move that facilitates the inclusion of BCI in regular medical services [5] - **Future Implications**: The successful surgery and its regulatory backing are expected to lay a crucial foundation for the large-scale clinical application of BCI technology in the future [5]

Group 1 - Shanghai Dongnao Zhihuo Technology Co., Ltd. has officially registered and established the Shanghai Brain-Computer Interface Future Industry Cluster, the first of its kind in the country, focusing on brain-computer interface technology development [2] - The company has gathered top talents from the semiconductor and neuroscience fields, with founder Gong Yi also serving as the chairman of Dongwei Semiconductor (stock code: 688261.SH) [2] - Dongnao Zhihuo aims to become a leading global brain-computer interface company by developing proprietary hydraulic-driven flexible neural interface electrode technology [2] Group 2 - Since the 12th Five-Year Plan, brain science and artificial intelligence research, including brain-computer interface technology, have gained increasing importance in China's national science and technology planning [3] - The government is supporting the industry through top-level design, with initiatives to promote the integration of brain-computer interfaces into medical insurance and the establishment of specialized wards [3] - The 2025 National Brain-Computer Interface Conference will be held in December at the Brain-Intelligence Heaven cluster, bringing together global experts and cutting-edge technology talents [3]

在 2025年11月于美国圣地亚哥举行的 第十二届国际神经工程大会 （ IEEE EMBS Neural Engineering Conference, NER 2025 ）上，中国 脑科学 创新企业 深圳市 应和脑科学 有限公司 （ Amygdala Neuro ，下文简称 "应和脑科学" ）正式报告 其自主研发的 介入脑机接口 ——颅内 血管支架电极 脑机 系统在大型动物模型中实现 长期植入 的关键成果 。该研究题为 《 Evaluation of a Novel Endovascular Electrode Array for Long-Term Cortical Recording and Stimulation 》 ，标志着应 和 脑科学介入脑机接口 在脑机接口（ BCI）核心技术领域取得实质性突破 ， 该工作不仅验证了 介入脑机接口 架构的长期可 行性，也为未来 BCI系统的临床转化提供了新路径。 本研究的核心在于首次在大型动物模型中验证了一种机械架构的颅内血管支架电极阵列具备近半年的双模态（ 记录 +刺激 ） 功能稳定性。相较于现有技术，其机械编织结构成本更低、工艺更灵活，有望加速国产化 BCI ...

"海淀既是国家人工智能发展高地，也是'AI+脑机数据'策源地。"海淀区委副书记、区政府党组书记许 心超表示，海淀区作为北京市医药健康产业核心承载区，形成了从研发到转化、从生产到应用的完整产 业链条，呈现出"基础学科全面、临床资源聚集、人才梯队完备"的独特优势，为"AI+脑机"技术的研发 与落地提供了肥沃土壤。 清华大学党委副书记、校长李路明表示，清华大学将不断加强脑机接口核心技术攻关，推进基础研究与 临床医学合作，围绕"AI+脑机数据"，持续加强创新平台建设，大力培养创新人才，努力产出更多标志 性、引领性的创新成果。 此外，信通院牵头，联合国内优势高校院所、医疗机构及创新企业，以标准、平台、生态为牵引，发起 筹备中关村脑机接口产业协会，将聚焦服务脑机接口技术协同攻关、成果转化落地、标准体系建设、专 业人才培养和产业创新生态搭建，推动产业链上下游协同发展。脑科学多模态通用基础大模型、脑疾病 AI精准诊疗系统等六项脑机接口创新成果集中亮相，展示北京在脑机接口领域从单点技术到系统集成 的自主创新能力。 新京报讯(记者吴为)北京市"AI+脑机"产业创新工作推进会11月21日在海淀举行。推进会以"脑智融合.慧 聚北京" ...

Core Viewpoint - The article highlights the advancements in brain-computer interface technology by Qiangnao Technology, led by founder Han Bicheng, emphasizing its practical applications in improving the quality of life for individuals with disabilities [1][18]. Company Background - Qiangnao Technology, founded in 2015, focuses on developing brain-computer interfaces, aiming to bridge the gap between neuroscience research and practical applications that can bring about positive changes in people's lives [3][4]. - The company name "BrainCo" is a direct abbreviation of "brain computer interface," clearly stating its core mission [4]. Product Development - The team dedicated seven to eight years to develop a bionic hand, which is crucial for individuals with disabilities, as the hand is the most complex part controlled by the brain [8][9]. - The first generation of the bionic hand weighs approximately 500 grams, while the second generation has been reduced to over 300 grams, making it more user-friendly [11]. User Experience - User testimonials, such as that of Ni Mincheng, who has been using the bionic hand since 2019, demonstrate significant improvements in daily life, including the ability to perform tasks like cooking and writing [12][15][20]. - The technology allows for intuitive control, enabling users to operate the hand as they think, with capabilities for simultaneous and independent finger movements [13][15]. Market Position and Strategy - Qiangnao Technology has established itself as a leading player in the industry, recognized among the "Six Little Dragons of Hangzhou," which includes companies with over ten years of experience [18]. - The company emphasizes continuous optimization of user experience and adapting technology to meet the diverse needs of users, including different limb conditions and environmental factors [20][23]. Competitive Landscape - Han Bicheng expresses a strong sense of urgency regarding competition, stating that the company must innovate and improve faster than others in the field [21][22]. - The focus remains on creating practical solutions rather than mere demonstrations, with a commitment to addressing real user needs [22][23].

Core Insights - The Percept™ RC, the world's first rechargeable and sensing closed-loop brain stimulator, has commenced clinical applications in major hospitals across Beijing, Anhui, and Shanxi as of November 2025 [1][4] - Developed by Medtronic, the device integrates artificial intelligence and brain-machine interface technology, and is approved by the Chinese National Medical Products Administration, the US FDA, and the EU CE for treating complex neurological disorders such as Parkinson's disease and drug-resistant epilepsy [3][4] - The device has been recognized as one of TIME magazine's "Best Inventions of 2025" and has been featured prominently at the China International Import Expo [3][4] Clinical Application - The clinical application of Percept™ RC marks a significant breakthrough in brain stimulator therapy, advancing the use of brain-machine interface technology for treating neurological diseases in China [4] - The device offers a more intelligent, precise, and comfortable treatment option for patients, enhancing the overall treatment experience [4][8] Technological Advancements - Compared to traditional brain stimulators, Percept™ RC provides real-time sensing and analysis of brain activity, allowing for personalized and precise treatment tailored to the patient's condition [8] - It is the smallest and lightest brain stimulator globally, being 37% smaller than traditional models, which improves patient comfort [8] - The device features an open lifespan battery technology and is fully compatible with 3.0T and 1.5T MRI scans, ensuring patient safety and access to future medical imaging [8] Historical Context - Deep brain stimulation (DBS), commonly known as "brain pacemaker," has been recognized as the preferred surgical treatment for Parkinson's disease since its first successful operation in 1987 [5] - The therapy has been clinically applied for over 35 years globally, with its introduction to China occurring in 1999 [5]